Skip to main content
SpringerLink
Log in

Ulcer Healing and Prevention in Systemic Sclerosis

  • Chapter
  • First Online:
Atlas of Ulcers in Systemic Sclerosis

Abstract

Digital ulcers (DU) have a major clinical impact in systemic sclerosis, and treatment and prevention are two logical and effective approaches to reduce the risk of complications and DU-related morbidity. Patient education, Raynaud’s phenomenon attacks control and identifications and treatment of potential risk factors for DU development are primary features of the above-mentioned approach. When this is not sufficient, different drug with shown evidences of efficacy in preventing or healing DU can be used, such as phosphodiesterase -5 inhibitors, endothelin-1 receptors antagonists and prostacyclin analogues, usually in combination with local topical treatment. Moreover, new approaches are also available, ranging from regenerative medicine to surgical procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Herrick AL. Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. Curr Opin Rheumatol. 2016;28(6):577–85.

    Article  CAS  Google Scholar 

  2. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160(8):1101–8.

    Article  Google Scholar 

  3. Caramaschi P, Martinelli N, Volpe A, et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol. 2009;28(7):807–13.

    Article  Google Scholar 

  4. Silva I, Almeida J, Vasconcelos C. A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev. 2015;14(2):140–52.

    Article  CAS  Google Scholar 

  5. Avouac J, Meune C, Ruiz B, et al. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis. 2012;71(3):394–9.

    Article  CAS  Google Scholar 

  6. Alivernini S, De Santis M, Tolusso B, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009;60(3):426–35.

    Article  Google Scholar 

  7. Smith V, Riccieri V, Pizzorni C, et al. Nail fold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J Rheumatol. 2013;40(12):2023–8.

    Article  Google Scholar 

  8. Sebastiani M, Manfredi A, Vukatana G, et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis. 2012;71(1):67–70.

    Article  CAS  Google Scholar 

  9. Cappelli S, Bellando-Randone S, Guiducci S, et al. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford). 2014;53(6):975–87. Review

    Article  Google Scholar 

  10. Guiducci S, Bellando Randone S, Bruni C, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol. 2012;31(12):1723–5.

    Article  CAS  Google Scholar 

  11. Parisi S, Peroni CL, Laganà A, et al. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology (Oxford). 2013;52(6):1142–4.

    Article  Google Scholar 

  12. Chung L, Ball K, Yaqub A, et al. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study. J Am Acad Dermatol. 2014;71(2):400–1.

    Article  CAS  Google Scholar 

  13. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35(9):1801–8.

    CAS  PubMed  Google Scholar 

  14. Tsifetaki N, Botzoris V, Alamanos Y, et al. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. J Rheumatol. 2009;36(7):1550–2.

    Article  Google Scholar 

  15. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford). 2008;47(4):464–6.

    Article  Google Scholar 

  16. Funauchi M, Kishimoto K, Shimazu H, et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int. 2009;29(7):769–75.

    Article  CAS  Google Scholar 

  17. Roman Ivorra JA, Simeon CP, Alegre Sancho JJ, et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol. 2011;38(8):1631–5.

    Article  Google Scholar 

  18. Cozzi F, Pigatto E, Rizzo M, et al. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol. 2013;32(5):679–83.

    Article  CAS  Google Scholar 

  19. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19(9):1407–14.

    CAS  PubMed  Google Scholar 

  20. Kawald A, Burmester GR, Huscher D, et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35(9):1830–7.

    CAS  PubMed  Google Scholar 

  21. Zachariae H, Halkier-Sørensen L, Bjerring P, et al. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol. 1996;76(3):236–8.

    CAS  PubMed  Google Scholar 

  22. Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001;28(10):2257–62.

    CAS  PubMed  Google Scholar 

  23. Rosato E, Borghese F, Pisarri S, et al. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009;28(12):1379–84.

    Article  Google Scholar 

  24. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69(8):1475–8.

    Article  CAS  Google Scholar 

  25. Kumar U, Sankalp G, Sreenivas V, et al. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Rheumatol Int. 2013;33(4):1047–52.

    Article  CAS  Google Scholar 

  26. Hachulla E, Hatron PY, Carpentier P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 2016;75(6):1009–15.

    Article  CAS  Google Scholar 

  27. Agarwal V, Parasar G, Aman S, et al. Efficacy of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis: A Double Blind Randomized Placebo Controlled Parallel Group Multicentric Study. Arthritis&Rheumatism. 2010;62(10):Supplement.

    Google Scholar 

  28. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49(12):2420–8.

    Article  CAS  Google Scholar 

  29. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985–93.

    Article  CAS  Google Scholar 

  30. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8.

    Article  CAS  Google Scholar 

  31. Guiducci S, Bellando Randone S, Bruni C, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol. 2012;31(12):1723–5.

    Article  CAS  Google Scholar 

  32. Cutolo M, Zampogna G, Vremis L, et al. Long term effects of endothelin receptor antagonism on microvascular damage evaluated by nail fold capillaroscopic analysis in systemic sclerosis. J Rheumatol. 2013;40(1):40–5.

    Article  CAS  Google Scholar 

  33. Khanna D, Denton CP, Merkel PA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA. 2016;315(18):1975–88.

    Article  CAS  Google Scholar 

  34. Woo TY, Wong RC, Campbell JP, et al. Nifedipine in scleroderma ulcerations. Int J Dermatol. 1984 Dec;23(10):678–80.

    Article  CAS  Google Scholar 

  35. Baron M, Skrinskas G, Urowitz MB, et al. Prostaglandin E1 therapy for digital ulcers in scleroderma. Can Med Assoc J. 1982;126(1):42–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Abuowda Y, Almeida RS, Oliveira AA, et al. Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome. Rev Assoc Med Bras (1992). 2017;63(5):422–6.

    Article  Google Scholar 

  37. Colaci M, Lumetti F, Giuggioli D, et al. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. Clin Exp Rheumatol. 2017;35 Suppl 106(4):179–83.

    PubMed  Google Scholar 

  38. Fraticelli P, Martino GP, Murri M, et al. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA). Clin Exp Rheumatol. 2017;35 Suppl 106(4):173–8.

    PubMed  Google Scholar 

  39. Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol. 2006;54(5):880–2.

    Article  Google Scholar 

  40. Shah AA, Schiopu E, Chatterjee S, et al. The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral Treprostinil. J Rheumatol. 2016;43(9):1665–71.

    Article  CAS  Google Scholar 

  41. Seibold R, Wigley FM, Schiopu E, et al. Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up. J Scleroderma Relat Disord. 2017;2(1):42–9.

    Article  Google Scholar 

  42. Cruz JE, Ward A, Anthony S, et al. Evidence for the use of epoprostenol to treat Raynaud's phenomenon with or without digital ulcers. Ann Pharmacother. 2016;50(12):1060–7.

    Article  CAS  Google Scholar 

  43. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol. 1999;26(10):2173–8.

    CAS  PubMed  Google Scholar 

  44. Fujimoto M, Asano Y, Ishii T, et al. The wound/burn guidelines - 4: guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. J Dermatol. 2016;43(7):729–57.

    Article  Google Scholar 

  45. Fiori G, Galluccio F, Braschi F, et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol. 2009;27(3 Suppl 54):51–4.

    CAS  PubMed  Google Scholar 

  46. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.

    Article  Google Scholar 

  47. Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43(1):56–62.

    Article  CAS  Google Scholar 

  48. Motegi SI, Uehara A, Yamada K, et al. Efficacy of Botulinum Toxin B injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis. Acta Derm Venereol. 2017;97(7):843–50.

    Article  CAS  Google Scholar 

  49. Giuggioli D, Colaci M, Manfredi A, et al. Platelet gel in the treatment of severe scleroderma skin ulcers. Rheumatol Int. 2012;32(9):2929–32.

    Article  CAS  Google Scholar 

  50. Ishigatsubo Y, Ihata A, Kobayashi H, et al. Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells. Mod Rheumatol. 2010;20(3):263–72.

    Article  Google Scholar 

  51. Takagi G, Miyamoto M, Tara S, et al. Therapeutic vascular angiogenesis for intractable macroangiopathy-related digital ulcer in patients with systemic sclerosis: a pilot study. Rheumatology (Oxford). 2014;53(5):854–9.

    Article  CAS  Google Scholar 

  52. Daumas A, Magalon J, Jouve E, et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr Res Transl Med. 2017;65(1):40–3.

    Article  CAS  Google Scholar 

  53. Del Papa N, Di Luca G, Sambataro D, et al. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant. 2015;24(11):2297–305.

    Article  Google Scholar 

  54. Fernandes das Neves M, Oliveira S, Amaral MC, et al. Treatment of systemic sclerosis with tocilizumab. Rheumatology (Oxford). 2015;54(2):371–2.

    Article  CAS  Google Scholar 

  55. Khor CG, Chen XL, Lin TS, et al. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol. 2014;33(7):1019–20.

    Article  Google Scholar 

  56. Ferri C, Giuggioli D, Sebastiani M, Colaci M. Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol. 2007;32(3):287–90.

    Article  CAS  Google Scholar 

  57. Mirasoglu B, Bagli BS, Aktas S. Hyperbaric oxygen therapy for chronic ulcers in systemic sclerosis - case series. Int J Dermatol. 2017;56(6):636–40.

    Article  CAS  Google Scholar 

  58. Pauling JD, Brown SJ, James J, et al. Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. Rheumatology (Oxford). 2011;50(2):420–2.

    Article  Google Scholar 

  59. Saito S, Tomonori I, Kenta I, et al. Extracorporeal shock wave therapy for digital ulcers associated with systemic sclerosis. J Scleroderma Relat Disord. 2016;1(2):181–5.

    Article  Google Scholar 

  60. Chiou G, Crowe C, Suarez P, et al. Digital Sympathectomy in patients with scleroderma: an overview of the practice and referral patterns and perceptions of rheumatologists. Ann Plast Surg. 2015;75(6):637–43.

    Article  CAS  Google Scholar 

  61. Barsotti S, Mattaliano V, d'Ascanio A, et al. Systemic sclerosis chronic ulcers: preliminary results of treatment with allogenic skin grafting in a cohort of Italian patients. Int Wound J. 2016;13(5):1050–1.

    Article  Google Scholar 

  62. Giuggioli D, Manfredi A, Colaci M, et al. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers. Pain Med. 2010;11(10):1500–3.

    Article  Google Scholar 

  63. Braschi F, Bartoli F, Bruni C, et al. Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. Clin Rheumatol. 2017;36(1):209–12.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy

    Cosimo Bruni

  2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Silvia Bellando-Randone & Marco Matucci-Cerinic

  3. Department of Geriatric Medicine, Division of Rheumatology AOUC, Florence, Italy

    Silvia Bellando-Randone & Marco Matucci-Cerinic

  4. Division of Medicine, University College London, Centre for Rheumatology, Royal Free Hospital, London, UK

    Christopher P. Denton

Authors
  1. Cosimo Bruni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Bellando-Randone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher P. Denton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Matucci-Cerinic
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Marco Matucci-Cerinic

  2. Division of Medicine, University College London, Centre for Rheumatology, Royal Free Hospital, London, UK

    Christopher P. Denton

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bruni, C., Bellando-Randone, S., Denton, C.P., Matucci-Cerinic, M. (2019). Ulcer Healing and Prevention in Systemic Sclerosis. In: Matucci-Cerinic, M., Denton, C. (eds) Atlas of Ulcers in Systemic Sclerosis. Springer, Cham. https://doi.org/10.1007/978-3-319-98477-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98477-3_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98475-9

  • Online ISBN: 978-3-319-98477-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation